bcda20231114_corresp.htm

0001437749-23-032039.txt : 20240108 0001437749-23-032039.hdr.sgml : 20240108 20231114170235 ACCESSION NUMBER: 0001437749-23-032039 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioCardia, Inc. CENTRAL INDEX KEY: 0000925741 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 232753988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 320 SOQUEL WAY CITY: SUNNYVALE STATE: CA ZIP: 94085 BUSINESS PHONE: 650-226-0123 MAIL ADDRESS: STREET 1: 320 SOQUEL WAY CITY: SUNNYVALE STATE: CA ZIP: 94085 FORMER COMPANY: FORMER CONFORMED NAME: Tiger X Medical, Inc. DATE OF NAME CHANGE: 20110616 FORMER COMPANY: FORMER CONFORMED NAME: Cardo Medical, Inc. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: CLICKNSETTLE COM INC DATE OF NAME CHANGE: 20000823 CORRESP 1 filename1.htm bcda20231114_corresp.htm

BioCardia, Inc.

320 Soquel Way

Sunnyvale, California 94085

November 14, 2023

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Cindy Polynice

	Re:	BioCardia, Inc.
		Registration Statement on Form S-3
		File No. 333-275099

		Acceleration Request

		Requested Date:	November 16, 2023
		Requested Time:	4:00 p.m.

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCardia, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-275099) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Michael J. Danaher at (650) 320-4625.

[Signature page follows]

	Sincerely,

	BioCardia, Inc.

	/s/ Peter Altman
	Peter Altman
	President and Chief Executive Officer and
	Director

cc:	David McClung, BioCardia, Inc.
	Michael J. Danaher, Wilson Sonsini Goodrich & Rosati, P.C.
	Austin D. March, Wilson Sonsini Goodrich & Rosati, P.C.